Pacific Biosciences of California, Inc. (PACB) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -133.04M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 88.36M USD | Research and Development Expense |
| Selling, general and administration | 129.70M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-133.04M | (m) | (m) | $88.36M | $129.70M | (m) |
| 2026-03-31 | $-133.28M | (m) | (m) | $87.86M | $132.48M | (m) |
| 2025-12-31 | $-553.86M | (m) | (m) | $97.31M | $141.49M | (m) |
| 2025-09-30 | $-665.69M | (m) | (m) | $101.89M | $149.08M | (m) |
| 2025-06-30 | $-690.89M | (m) | (m) | $104.56M | $161.73M | (m) |
| 2025-03-31 | $-821.88M | (m) | (m) | $120.52M | $171.43M | (m) |
| 2024-12-31 | $-474.31M | (m) | (m) | $134.92M | $175.02M | (m) |
| 2024-09-30 | $-408.83M | (m) | (m) | $152.00M | $179.37M | (m) |
| 2024-06-30 | $-427.25M | (m) | (m) | $174.00M | $179.06M | (m) |
| 2024-03-31 | $-324.58M | (m) | (m) | $181.69M | $173.75M | (m) |
| 2023-12-31 | $-334.47M | (m) | (m) | $187.17M | $169.82M | (m) |
| 2023-09-30 | $-334.00M | (m) | (m) | $185.25M | $168.82M | (m) |
| 2023-06-30 | $-326.13M | (m) | (m) | $184.83M | $162.19M | (m) |
| 2023-03-31 | $-320.93M | (m) | (m) | $189.00M | $160.87M | (m) |
| 2022-12-31 | $-307.20M | (m) | (m) | $193.00M | $160.85M | (m) |
| 2022-09-30 | $-284.79M | (m) | (m) | $192.95M | $153.17M | (m) |
| 2022-06-30 | $-284.64M | (m) | (m) | $173.37M | $147.98M | (m) |
| 2022-03-31 | $-254.25M | (m) | (m) | $145.29M | $137.79M | (m) |
| 2021-12-31 | $-210.44M | (m) | (m) | $112.90M | $124.12M | (m) |
| 2021-09-30 | $-169.74M | (m) | $68.14M | $87.75M | $104.76M | (m) |
| 2021-06-30 | $-119.44M | (m) | $60.63M | $76.71M | $87.92M | (m) |
| 2021-03-31 | $-105.39M | (m) | $54.24M | $69.45M | $73.99M | (m) |
| 2020-12-31 | $-104.39M | (m) | $46.33M | $64.15M | $72.80M | (m) |
| 2020-09-30 | $-98.33M | (m) | $45.59M | $61.00M | $71.42M | (m) |
| 2020-06-30 | $-102.26M | (m) | $48.57M | $59.49M | $76.72M | (m) |
| 2020-03-31 | $-103.12M | (m) | $53.12M | $59.40M | $80.67M | (m) |
| 2019-12-31 | $-100.55M | (m) | $56.31M | $59.63M | $75.49M | (m) |
| 2019-09-30 | $-113.25M | $82.49M | $55.10M | $61.62M | $79.02M | -137.30% |
| 2019-06-30 | $-109.81M | $78.73M | $55.06M | $61.01M | $72.46M | -139.47% |
| 2019-03-31 | $-107.17M | $75.69M | $52.77M | $61.77M | $68.32M | -141.60% |
| 2018-12-31 | $-100.99M | $78.63M | $53.53M | $62.59M | $63.49M | -128.44% |
| 2018-09-30 | $-90.89M | $84.03M | (m) | $61.96M | $57.78M | -108.16% |
| 2018-06-30 | $-87.79M | $89.42M | (m) | $63.45M | $58.23M | -98.18% |
| 2018-03-31 | $-90.43M | $87.92M | (m) | $64.66M | $58.79M | -102.87% |
| 2017-12-31 | $-89.78M | $93.47M | (m) | $65.32M | $59.12M | -96.06% |
| 2017-09-30 | $-87.13M | $94.25M | (m) | $65.95M | $57.72M | -92.44% |
| 2017-06-30 | $-82.30M | $95.83M | (m) | $67.59M | $55.66M | -85.88% |
| 2017-03-31 | $-75.98M | $96.50M | (m) | $68.23M | $51.34M | -78.73% |
| 2016-12-31 | $-71.24M | $90.71M | (m) | $67.62M | $47.79M | -78.54% |
| 2016-09-30 | $-54.43M | $101.27M | (m) | $66.11M | $47.57M | -53.75% |
| 2016-06-30 | $-35.08M | $90.07M | (m) | $64.80M | $46.49M | -38.95% |
| 2016-03-31 | $-28.37M | $94.26M | (m) | $62.32M | $46.12M | -30.10% |
| 2015-12-31 | $-29.13M | $92.78M | (m) | $60.44M | $45.19M | -31.40% |
| 2015-09-30 | $-45.97M | $73.41M | (m) | $58.02M | $42.41M | -62.62% |
| 2015-06-30 | $-56.99M | $80.11M | (m) | $53.55M | $41.48M | -71.14% |
| 2015-03-31 | $-63.94M | $66.60M | (m) | $50.94M | $39.65M | -96.01% |
| 2014-12-31 | $-62.85M | $60.59M | (m) | $48.23M | $38.03M | -103.73% |
| 2014-09-30 | $-61.96M | $52.82M | (m) | $47.03M | $37.09M | -117.30% |
| 2014-06-30 | $-73.49M | $39.62M | (m) | $45.76M | $37.96M | -185.47% |
| 2014-03-31 | $-75.18M | $34.24M | (m) | $45.01M | $38.34M | -219.54% |
| 2013-12-31 | $-77.54M | $28.18M | (m) | $45.22M | $38.74M | -275.16% |
| 2013-09-30 | (m) | $24.93M | (m) | $45.74M | $40.35M | (m) |
| 2013-06-30 | (m) | $20.28M | (m) | $47.94M | $39.74M | (m) |
| 2013-03-31 | (m) | $21.52M | (m) | $47.53M | $41.92M | (m) |
| 2012-12-31 | (m) | $25.98M | (m) | $47.62M | $47.66M | (m) |
| 2012-09-30 | (m) | $32.55M | (m) | $48.39M | $48.80M | (m) |
| 2012-06-30 | (m) | $40.29M | (m) | $55.76M | $51.42M | (m) |
| 2012-03-31 | (m) | $43.63M | (m) | $64.03M | $50.88M | (m) |
| 2011-12-31 | (m) | $33.86M | (m) | $76.08M | $46.71M | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $1.67M | (m) | $111.82M | $30.09M | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $135.00K | (m) | $75.88M | $12.33M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |